Front. Mol. Neurosci. Frontiers in Molecular Neuroscience Front. Mol. Neurosci. 1662-5099 Frontiers Media S.A. 10.3389/fnmol.2017.00311 Neuroscience Mini Review The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology Manecka Destiny-Love † Vanderperre Benoît † Fon Edward A. Durcan Thomas M. * Neurodegenerative Diseases Group and iPSC-CRISPR Core Facility, Montreal Neurological Institute, McGill University, Montreal, QC, Canada

Edited by: Paola Rusmini, Università degli Studi di Milano, Italy

Reviewed by: Ralf J. Braun, University of Bayreuth, Germany; Maciej Maurycy Lalowski, University of Helsinki, Finland

*Correspondence: Thomas M. Durcan, thomas.durcan@mcgill.ca

†These authors have contributed equally to this work.

 27 09 2017 2017 10 311 19 05 2017 14 09 2017 Copyright © 2017 Manecka, Vanderperre, Fon and Durcan. 2017 Manecka, Vanderperre, Fon and Durcan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Synucleinopathies are a family of neurodegenerative disorders that comprises Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Each of these disorders is characterized by devastating motor, cognitive, and autonomic consequences. Current treatments for synucleinopathies are not curative and are limited to improvement of quality of life for affected individuals. Although the underlying causes of these diseases are unknown, a shared pathological hallmark is the presence of proteinaceous inclusions containing the α-synuclein (α-syn) protein in brain tissue. In the past few years, it has been proposed that these inclusions arise from the self-templated, prion-like spreading of misfolded and aggregated forms of α-syn throughout the brain, leading to neuronal dysfunction and death. In this review, we describe how impaired protein homeostasis is a prominent factor in the α-syn aggregation cascade, with alterations in protein quality control (PQC) pathways observed in the brains of patients. We discuss how PQC modulates α-syn accumulation, misfolding and aggregation primarily through chaperoning activity, proteasomal degradation, and lysosome-mediated degradation. Finally, we provide an overview of experimental data indicating that targeting PQC pathways is a promising avenue to explore in the design of novel neuroprotective approaches that could impede the spreading of α-syn pathology and thus provide a curative treatment for synucleinopathies.

 α-synuclein protein quality control Lewy body Parkinson’s disease chaperone autophagy lysosome 12241 MFE 152571 Michael J. Fox Foundation for Parkinson’s Research10.13039/100000864 Canadian Institutes of Health Research10.13039/501100000024 Introduction

Maintaining protein homeostasis is essential for normal cellular function and viability. This is overseen by PQC mechanisms, through the control of protein synthesis, localization, folding/refolding, degradation and formation of protein inclusions. At the post-translational level, PQC is orchestrated by several mechanisms including chaperones that maintain correct protein conformation or help refold misfolded proteins; and the UPS and ALP, which degrade proteins that are irreversibly misfolded, damaged, or are no longer required by the cell. In this review, we focus on these aspects of PQC; with other PQC pathways reviewed elsewhere (Wolff et al., 2014; Dubnikov et al., 2017). In eukaryotes, protein chaperones are essential for ensuring the correct folding of nascent proteins and refolding of misfolded proteins. Hsps or heat shock chaperones (Hscs) are a prominent group of chaperones and they can be found in the ER, mitochondria, cytoplasm or extracellular space (Hartl et al., 2011; Wyatt et al., 2013). Protein degradation through the UPS is regulated by the sequential activity of E1, E2, and E3 enzymes that conjugate primarily K48-linked ubiquitin (Ub) chains onto lysine residues in proteins destined for elimination through the 26S proteasome (Passmore and Barford, 2004). The ALP acts mainly through macroautophagy and CMA. In macroautophagy, cytoplasmic content (including soluble and aggregated proteins) is engulfed by a double-membrane to form an autophagosome that fuses with the lysosome forming an autolysosome, degrading the autophagosomal content (Bento et al., 2016). In CMA, Hsc70 specifically binds to and targets proteins containing KFERQ-like motifs to the lysosomal receptor Lamp2A for client import through the lysosomal membrane, and subsequent degradation by lysosomal hydrolases (Cuervo and Wong, 2014). In addition, chaperones and ubiquitination systems promote the spatial sequestration of misfolded proteins into inclusions (aggresome/Q-bodies) and mediate the lysosomal degradation of toxic aggregates through the aggresome–autophagy and multivesicular body pathways (Johnston et al., 1998; Sahu et al., 2011; Escusa-Toret et al., 2013; Sontag et al., 2017). These pathways are regulated by K63-linked Ub chains and are critical for the degradation of aggregated proteins including α-synuclein (α-syn) (Tanaka et al., 2004; Filimonenko et al., 2007; Tofaris et al., 2011). Inefficient PQC is implicated in protein toxicity, gain- or loss-of-function in many pathologies, including several neurodegenerative diseases known as synucleinopathies. Synucleinopathies, which include PD, LBD and MSA, are characterized by the pathologic accumulation and aggregation of α-syn (McCann et al., 2014). As some mutations altering PQC machinery are associated with familial forms of synucleinopathies and α-syn pathologic aggregates impair PQC, targeting the PQC machinery has become a promising therapeutic strategy for opposing the toxic effects of misfolded α-syn aggregates (Figure 1).

Principal PQC mechanisms involved in α-syn homeostasis and potential therapeutic approaches. In physiologic conditions, misfolded α-syn protein is degraded by PQC machinery: the UPS is responsible for ubiquitination of α-syn leading to proteasomal degradation of α-syn, while macroautophagy and CMA both lead to lysosomal degradation of misfolded α-syn. In synucleinopathies, alterations in these protective mechanisms result in the accumulation of misfolded α-syn in aggregates and Lewy bodies (LB) that lead to neuronal dysfunction and death. Genetic or pharmaceutical approaches to restore altered PQC pathways or stimulate alternative PQC pathways: (1) Inhibition of α-syn expression could prevent its pathological accumulation. (2) Overexpression of Lamp2A lysosomal receptor could increase the CMA of misfolded α-syn. (3) Pharmaceutical inhibition of mTOR, an autophagy receptor, stimulates macroautophagy preventing α-syn accumulation and aggregation. (4) Overexpression of the transcription factor NRF2 activates both macroautophagy and CMA and stimulates the lysosomal degradation of misfolded α-syn. (5) Improving lysosomal hydrolases activity or (6) stimulating lysosomal biogenesis could also enhance α-syn lysosomal degradation. α-syn aggregation can also be prevented by stimulation or overexpression of (7) endogenous or (8) secretory chaperones.

 Misfolding and Spreading of α-syn in Synucleinopathies

α-syn, a 140-amino acid protein encoded by the SNCA gene, is abundant in the human brain (1% of all cytosolic proteins) (Stefanis, 2012) and is implicated in various cellular processes including vesicular trafficking, dopamine release and reuptake (Abeliovich et al., 2000; Senior et al., 2008; DeWitt and Rhoades, 2013; Burré et al., 2014). α-syn is structured into three domains: the N-terminal amphipathic domain, which allows membrane-binding; the central hydrophobic non-amyloid-β component (NAC) domain, essential for α-syn aggregation; and the acidic, negatively charged C-terminal domain, that is critical for chaperone-like activity during thermal and chemical stress (Souza et al., 2000; Ahn et al., 2006; Beyer, 2006). Under physiological conditions, α-syn is soluble and intrinsically disordered, or can adopt an N-terminal α-helix conformation with high affinity for biological membranes (Bartels et al., 2011). In synucleinopathies, α-syn follows sequential aggregation/fibrillization, starting from soluble monomers, dimers, and misfolded oligomers that aggregate into insoluble protofibrils and fibrils with an anti-parallel β-sheet structure (Dettmer et al., 2015; Rodriguez et al., 2015; Roeters et al., 2017).

Aggregation of α-syn leads to the formation of proteinaceous inclusions termed Lewy bodies (LB) and Lewy neurites (Wakabayashi et al., 1998). In PD, α-syn pathology has been shown to spread from brainstem to neocortex following a specific pattern (Braak et al., 2003). Recent evidence suggests that this is due to the prion-like, cell-to-cell propagation of α-syn aggregates (Masuda-Suzukake et al., 2013; Goedert et al., 2016). This concept was established in cells containing α-syn fibrils that secrete α-syn seeds taken up by surrounding healthy cells. In these recipient cells, exogenous protofibrils seed the aggregation of endogenous soluble α-syn monomers, causing α-syn to adopt an insoluble β-sheet conformation. This results in the formation of new α-syn seeds, which spread into neighboring cells (Volpicelli-Daley et al., 2011; Luk et al., 2012a,b; Mougenot et al., 2012).

 Targeting PQC Defects as Potential Neuroprotective Strategies Against α-syn Pathology Chaperones

The first indication that chaperones confers neuroprotection in α-syn–induced pathogenesis was Hsp70 overexpression protecting against α-syn toxicity in Drosophila (Auluck et al., 2002). Accordingly, modulating chaperone function through chemical or genetic approaches holds great therapeutic promise for synucleinopathies. Chaperones ensure the correct folding of nascent and mature protein chains (Ebrahimi-Fakhari et al., 2011; Sharma and Priya, 2017). They also prevent seeding of new aggregates and fibrillization by occluding surfaces that may serve as platforms to induce misfolding of native proteins (Hartl et al., 2011). To some extent, Hsp110, Hsp70 and Hsp40 chaperones can disassemble α-syn fibrillary aggregates in vitro (Duennwald et al., 2012; Gao et al., 2015). Enhancing disaggregase activity genetically or with pharmacological modulators could counteract α-syn aggregation (Gao et al., 2015; Jackrel and Shorter, 2015; Shorter, 2016; Sharma and Priya, 2017). Whether disaggregation occurs in vivo remains to be established, and since this process might generate soluble, potentially toxic forms of misfolded α-syn, simultaneous enhancement of α-syn degradation is likely necessary for beneficial effects.

Targeting Hsp70/Hsp90 signaling is of prime interest, not only in synucleinopathies, but also in other adult-onset proteinopathies (Pratt et al., 2015). These chaperones have opposing effects: Hsp90 stabilizes its clients, whereas Hsp70 directs them for proteasomal degradation upon Hsp90 dissociation. In yeast, cellular, or animal models of PD, inhibiting Hsp90 activity (Auluck and Bonini, 2002; Auluck et al., 2005; Putcha et al., 2010) or stimulating Hsp70 activity (Auluck et al., 2002; McLean et al., 2002; Klucken et al., 2004; Zhou et al., 2004, 2011; Shin et al., 2005; Yu et al., 2005; Batelli et al., 2008; Outeiro et al., 2008) and that of its collaborator Hsp40 (McLean et al., 2002; Fan et al., 2006) reduces α-syn oligomerization, inclusions formation, and toxicity, and diminishes α-syn levels (Table 1). Although induction of chaperone expression in various cellular locations during proteotoxic stress and its associated stress response is observed in the brains of patients affected by synucleinopathies, α-syn aggregates still accumulate, indicating that the chaperone machinery is overwhelmed. This is supported by findings that many chaperones (including Hsp70, Hsp90 and Hsp40) or mediators of the heat-shock response (HDAC6) are found in LBs (Table 1), possibly reflecting a cellular attempt to sequester soluble, harmful misfolded species of α-syn (Escusa-Toret et al., 2013). Other chaperones can also mitigate α-syn aggregation and toxicity in various models (see Table 1). Overall, it appears evident that modulation of chaperone function is an innovative therapeutic approach against α-syn toxicity. In a clinical context, where widespread α-syn aggregation has already occurred, a global increase in chaperoning activity such as stimulation of the heat-shock response (Du et al., 2014) might have a greater impact than manipulation of individual chaperones. The use of pharmacological chaperones (e.g., flavonoids or polyphenols, Caruana et al., 2011; Ren et al., 2016; Gautam et al., 2017) to prevent or revert α-syn aggregation may also complement therapeutic modulation of endogenous chaperones.

Therapeutic avenues for targeting PQC pathways in the treatment of synucleinopathies.

Target Physiological function Implication in disease Therapeutic strategies Therapeutic effect Reference
Chaperoning
Hsp70 (HSPA1A) Directs client proteins for degradation by the UPS; serves as a disaggregase against fibrillary aggregates Component of Lewy bodies in PD Induction of expression by small molecules (e.g., geldanamycin)10; genetic overexpression1,3,6,8; induction by cell-penetrating recombinant DJ-1 protein2 (PARK7), by phenylbutyrate-induced DJ-1 expression9, or by CHIP overexpression6 Protects against α-syn toxicity in Drosophila melanogaster despite the presence of inclusions1; reduces insolubility of α-syn in α-syn overexpressing mice3; prevents α-syn accumulation and aggregation in human H4 neuroglioma cells4,5 and dopaminergic MES cells; in dopaminergic N27 cells, protects against α-syn toxicity9; in SK-N-SH cells7, prevents oxidative stress, dopamine (DA) loss and cell death2 Auluck et al., 20021, 200510; McLean et al., 20024; Klucken et al., 20043; Zhou et al., 20048, 20119; Shin et al., 20056; Yu et al., 20057; Batelli et al., 20082; Outeiro et al., 20085; Duennwald et al., 2012; Gao et al., 2015; Jackrel and Shorter, 2015; Shorter, 2016; Sharma and Priya, 2017
Hsp90 (HSP90AB 1) Stabilizes client proteins by preventing Hsp70-mediated UPS targeting; favors fibrillization of α-syn, shifting the aggregation eqilibrium away from early toxic soluble misfolded species Component of Lewy bodies in PD, increase in insoluble fraction in temporal cortex from LBD Inhibition by small molecules (e.g., geldanamycin)10 Reduces α-syn aggregation and toxicity in human H4 cells11; protects against α-syn toxicity in D. melanogaster despite the presence of inclusions10 Auluck and Bonini, 2002; Auluck et al., 2005; Cantuti-Castelvetri et al., 200511; Putcha et al., 2010; Gao et al., 2015
Hsp40 (DNAJB1) With Hsp70, targets client proteins for UPS-mediated degradation; participates in α-syn disaggregation together with Hsp110 and Hsp70 Component of Lewy bodies in PD Overexpression by transfection4,12 Reduces α-syn aggregation in human H4 cells4; lowers α-syn accumulation and aggregation in SK-N-SH cells12 McLean et al., 20024; Fan et al., 200612; Duennwald et al., 2012; Jackrel and Shorter, 2015; Shorter, 2016; Sharma and Priya, 2017
Torsin-1A (TOR1A) Chaperone with ATPase activity, homolog of yeast Hsp104 Component of Lewy bodies and Lewy neurites in LBD Overexpression by transfection12 Reduces α-syn aggregation in human H4 cells McLean et al., 2002
proSAAS (PCSK1N) Neural-specific secretory chaperone, prevents α-syn aggregation Component of Lewy bodies in PD Overexpression using viral vector; extracellular treatment with recombinant proSAAS13 Blocks α-synuclein-induced cytotoxicity in primary cultures of nigral dopaminergic neurons and in dopaminergic SH-SY5Y cells13 Jarvela et al., 201613
ERdj5 (DNAJC10) Endoplasmic reticulum-resident thioredoxin disulfide reductase, regulates degradation of misfolded proteins via ERAD (endoplasmic-reticulum associated degradation) Unknown Overexpression in transgenic C. elegans14 Protects against α-syn aggregation and toxicity, restoring age-dependent mobility defects and loss of dopaminergic neurons in Caenorhabditis elegans14 Munoz-Lobato et al., 201414
GRP78 (HSPA5) Endoplasmic reticulum-resident chaperone, induced during the Unfolded Protein Response Unknown Recombinant Adeno-Associated Viruses (rAAV)-mediated overexpression in the substantia nigra (SN) In rats overexpressing α-syn in the substantia nigra, co-overexpression of GRP78 attenuates α-syn-induced dopaminergic neuron loss and motor deficits15 Gorbatyuk et al., 2012; Salganik et al., 201515
TRAP-1 (TRAP1) Mitochondrial Hsp75 chaperone with ATPase activity Unknown Overexpression16 Suppresses α-syn toxicity in mutant A53T α-syn expressing D. melanogaster, rat primary neurons and HEK293 cells16 Butler et al., 201216
HDAC6 (HDAC6) Histone deacetylase, mediates α-syn degradation by inducing the Heat Shock Response Component of Lewy bodies in PD Overexpression by transfection17 Decreases α-syn oligomers and toxicity in SK-N-SH cells17 Miki et al., 2011; Du et al., 201417
Ubiquitin-Proteasome System
UCHL1 (UCHL1) Ubiquitin carboxy-terminal hydrolase, involved in the processing of ubiquitin precursors and ubuquitinated proteins Mutated in an autosomal-dominant form of PD, component of LB in sporadic PD Pharmacological inhibition using LDN-5744418 In primary neurons and hippocampal tissue of α-syn overexpressing mice, enhanced synaptic clearance of α-syn18 Maraganore et al., 2004; Xia et al., 2008; Cartier et al., 201218; Kumar et al., 2017
CHIP (STUB1) E3 ubiquitin-protein ligase, targets toxic α-syn oligomers toward proteasome- and ALP-mediated degradation Component of Lewy bodies in PD Gene therapy (overexpression using a viral vector)19 Mediates the degradation of α-syn in vivo in rats, but also induces tyrosine hydroxylase degradation, limiting its therapeutic interest19 Shin et al., 2005; Tetzlaff et al., 2008; Dimant et al., 201419
USP9X (USP9X) Deubiquitinates α-syn, preventing its degradation by the proteasome Decreased activity in PD and LBD, component of LB Overexpression by transfection20 Decreases α-syn aggregation and toxicity in SH-SY5Y dopaminergic cells upon proteolytic impairment20 Rott et al., 201120
Macroautophagy
mTOR (MTOR) Serine/Threonine kinase which acts as an autophagy repressor Decreased activity in patient-derived GBA mutant fibroblasts Inhibition using rapamycin21,22 Autophagic clearance of α-syn, protection of DA neurons and improvement in motor function in rodents21,22 (with possible adverse effects) Kahan, 2011; Decressac et al., 201321; Magalhaes et al., 2016; Tian et al., 201622
SIRT2 (SIRT2) Deacetylates α-syn on lysines 6 and 10 Unknown Knock-out in mice23 In mice, protects against DA neurons loss caused by overexpression of α-syn in the SN, or by MPTP injection23 de Oliveira et al., 201723
PLK2 (PLK2) Phosphorylates α-syn at S129 to stimulate its removal by autophagy Upregulated in LBD- affected brains AAV-mediated overexpression in the SN24 Reduces α-syn accumulation, DA neurons loss and motor deficits in a rat genetic model of PD24 Mbefo et al., 2010; Oueslati et al., 201324; Dahmene et al., 2017
Beclin-1 (BECN1) Regulates the PI3K complex, stimulating autophagosome formation Unknown Overexpression (lentivirus)25 Reduces α-syn accumulation, ALP defects and neuronal pathology in α-syn transgenic mice25 Spencer et al., 200925
Spermidine Activates autophagy, counteracting age-assocaited cell death Unknown Spermidine administration26 Rescues α-syn toxicity, motor deficits and loss of DA neurons in C. elegans and D. melanogaster26 Büttner et al., 201426
Chaperone-mediated autophagy
Lamp2A (LAMP2) CMA receptor, rate-limiting factor of CMA. Translocates α-syn into lysosomes for degradation Decreased levels correlate with α-syn accumulation in PD Overexpression using AAV or rAAV27 Upregulates CMA activity, reducing α-syn levels and α-syn toxicity in SH-SY5Y DA cells, rat primary cortical and nigral DA neurons27 Xilouri et al., 201327; Murphy et al., 2014; Xilouri et al., 2016
Targets: main PQC pathways and biological targets with therapeutic potential. Physiologic function: function of the target with respect to α-syn–relevant biological pathways. Implication in disease: pathologic evidence for the implication of the target in patients with synucleinopathies. Therapeutic strategies: describes experimental strategies used to manipulate a given target. Therapeutic effect: describes biologic effects on α-syn pathology observed upon application of the corresponding therapeutic strategies. Superscript numbers indicate the corresponding references for each model. The corresponding human Gene Symbol related to proteins of interest is indicated in parentheses. Ubiquitin-Proteasome System

Dysfunction in the UPS contributes to α-syn pathology with proteasomal subunits and ubiquitinated α-syn observed in LBs (Ii et al., 1997; Hasegawa et al., 2002). In sporadic PD, 20S and 26S proteasome activity are reduced, and α-syn aggregates can inhibit proteasome function (Bence et al., 2001; Tanaka et al., 2001). Many dysfunctions in Ub ligases (specifically E3s) have been linked to α-syn quality control. Indeed, various E3s have been identified in LBs, including CHIP (Table 1), E6AP and SIAH (Schlossmacher et al., 2002; Liani et al., 2004; Shin et al., 2005; Mulherkar et al., 2009). CHIP, a co-chaperone with E3 Ub ligase activity, regulates α-syn proteasomal degradation, in collaboration with Hsc70, Hsp70, and Hsp90. Like CHIP, E6AP triggers α-syn degradation while SIAH monoubiquitinates α-syn to promote its aggregation (Rott et al., 2008; Mulherkar et al., 2009). Mutations in the gene encoding Parkin E3 Ub ligase are responsible for inherited PD (Olzmann et al., 2007; Lonskaya et al., 2013). Although these loss-of-function mutations are associated with PD, they do not lead to LB pathology (Shimura et al., 2000). It has been suggested that Parkin K63-linked polyubiquitination favors LB formation (Olanow et al., 2004; Kramer and Schulz-Schaeffer, 2007; Olzmann and Chin, 2008), and deficient Parkin activity would favor accumulation of earlier, potentially toxic aggregation intermediates. However, this awaits further confirmation, and to date, the role of Parkin Ub-ligase activity in mitochondrial quality control (Roberts et al., 2016) appears more relevant to PD pathogenesis than in LB formation.

Since proteasomes can degrade α-syn (Bennett et al., 1999), and regulation of α-syn ubiquitination has been implicated in PD (Liani et al., 2004; Rott et al., 2008, 2011), enhancing UPS activity could stimulate α-syn degradation and reduce aggregation-linked pathology (Opattova et al., 2015). Non-aggregated α-syn could be specifically targeted to the proteasome, thereby preventing aggregated α-syn from further inhibiting proteasome catalytic activity (Stefanis et al., 2001; Snyder et al., 2003; Chen et al., 2006). Selective enhancement of α-syn targeting to proteasomes is a more desirable approach to broader enhancement of UPS activity, which may lead to serious adverse effects. This could be achieved by increasing the activity of the specific machinery that controls the ubiquitination of α-syn, such as the druggable deubiquitinase USP9X (Rott et al., 2011, Table 1), although only inhibitors have been reported so far (Peterson et al., 2015). Deubiquitination of α-syn might redirect the α-syn burden toward the ALP, which is generally recognized as a more efficient α-syn degradation pathway than the UPS (Vogiatzi et al., 2008). It should be noted that α-syn ubiquitination can serve as a signal for lysosome-dependent degradation (Tofaris et al., 2011; Braun, 2015; Alexopoulou et al., 2016), illustrating a complex cross-talk between post-translational modifications of α-syn and cellular degradation machineries (Choi et al., 2012; Haj-Yahya et al., 2013; Shahpasandzadeh et al., 2014; Tenreiro et al., 2014; de Oliveira et al., 2017). It remains unclear which α-syn degradation pathway is favored, therefore further study is needed before a viable therapeutic strategy can be designed to enhance UPS-mediated α-syn degradation.

 Autophagy-Lysosome Pathway

The ALP is thought to be the most efficient pathway for degradation of α-syn (Vogiatzi et al., 2008), with dysfunction causing accumulation and aggregation of α-syn. Defects in the ALP have been linked with an increasing number of genetic variants identified as causative or associated with PD risk (Gan-Or et al., 2015), including Vps35, a component of the retromer that mediates retrograde transport from endosomes to Golgi, the lysosomal ATPase pump ATP13A2, and LRRK2 (Ramirez et al., 2006; Usenovic et al., 2012; Orenstein et al., 2013; Kong et al., 2014; Tsunemi and Krainc, 2014; Tang et al., 2015; Follett et al., 2016). Polymorphisms in genes encoding lysosomal enzymes, acid sphingomyelinase (SMPD1 gene), and β-glucocerebrosidase (GBA, GBA1 gene), are also risk factors for synucleinopathies (Neumann et al., 2009; Dagan et al., 2015; Gan-Or et al., 2015). A reduction in GBA expression and activity is observed in the substantia nigra and cerebellum of patients with sporadic PD (Gegg et al., 2012), and the inhibition of GBA or its transporter Limp2 is sufficient to stimulate α-syn aggregation through autophagic inhibition (Rothaug et al., 2014; Du et al., 2015). Polymorphisms in the lysosomal K+ channel encoding gene TMEM175 are risk factors for PD (Nalls et al., 2014). TMEM175 deficiency causess ALP dysfunction and increased α-syn aggregation (Jinn et al., 2017). Additional ALP-related genes were just recently linked to PD (Chang et al., 2017), converging into a unifying theory for PD pathogenesis, where the ALP is challenged by defects in synaptic exocytosis, endocytosis, and endosomal trafficking, resulting in neuron dysfunction and death (Trinh and Farrer, 2013).

Macroautophagy is responsible for degrading most of the aggregated, proteasome-resistant, α-syn, and enhancing this process represents a promising therapeutic strategy (Figure 1 and Table 1). The mTOR inhibitor rapamycin activates macroautophagy, prevents α-syn accumulation and aggregation, and ameliorates motor symptoms, but adverse effects have been reported (Kahan, 2011; Li et al., 2014; Tian et al., 2016). More recently, it was shown that acetylation of α-syn increases macroautophagy-mediated degradation of α-syn aggregates, with knock-out of the α-syn deacetylase SIRT2 protects against α-syn–induced dopaminergic cell loss in vivo (de Oliveira et al., 2017, see Table 1). Independent from UPS-targeting, modulation by the deubiquitinase USP8 and the Ub-ligase Nedd4 of α-syn modification by K63-linked Ub appears to control its autophagic degradation (Braun, 2015; Alexopoulou et al., 2016). A better understanding of the specific effects of various post-translational modifications will be necessary to appropriately modulate α-syn clearance by macroautophagy.

CMA specifically degrades physiologic α-syn (which contains a KFERQ-like motif, VKKDQ), whereas pathologic α-syn inhibits CMA, thus enhancing aggregation of itself and other LB components (Martinez-Vicente et al., 2008; Vogiatzi et al., 2008; Xilouri et al., 2009). Accordingly, overexpression of certain PD-associated microRNAs is suspected to be responsible for pathologic CMA downregulation through decreased Hsc70 and Lamp2A expression. This correlates with α-syn accumulation in brains of patients with PD (Alvarez-Erviti et al., 2013; Murphy et al., 2015). CMA-mediated degradation of α-syn and LRRK2 is also impaired by mutants of these proteins that cause inherited PD (A53T and A30P α-syn mutants; G2019S and R1441C LRRK2 mutants). These mutants are recognized by Hsc70 and targeted to the lysosomal membrane, but fail to be translocated into the lysosome due to an aberrantly high affinity for Lamp2A. This impairs CMA-mediated degradation of these proteins and CMA activity, contributing to PD pathology (Cuervo et al., 2004; Orenstein et al., 2013). Deficiencies in CMA (caused by LRRK2 or VPS35 PD-associated mutations for example, Orenstein et al., 2013; Tang et al., 2015; Ho et al., 2016) cause accumulation of α-syn, favoring the emergence of aberrant α-syn species that hinder the function of the Lamp2A receptor. Lamp2A overexpression efficiently prevents α-syn burden in cellular and animal models of PD and counteracts motor deficits (see Table 1). Whether this strategy can reverse α-syn pathology in a clinical context, in a safe and effective way, still needs to be determined, especially since CMA cannot mediate the degradation of aggregated species. The role of CMA in PD pathogenesis has been reviewed recently (Sala et al., 2016), and will not be discussed further here. Notably, strategies aiming at activating both macroautophagy and CMA are also being explored (Gan et al., 2012; Lastres-Becker et al., 2016), such as overexpression of the transcription factor NRF2, which protects against α-syn pathology and increases its turnover through unknown ALP-dependent mechanisms (Skibinski et al., 2017).

A prerequisite for efficient α-syn degradation by ALP is the adequate function and hydrolytic capacity of lysosomes. Improper activity of lysosomal hydrolases, due to mutations, sorting defects, or altered lysosomal homeostasis, has emerged as a critical step in the development of PD (Trinh and Farrer, 2013; Gan-Or et al., 2015) and other synucleinopathies, particularly those associated with lysosomal storage disorders (Gaucher disease, Niemann-Pick disease; Cullen et al., 2011; Osellame and Duchen, 2013; Osellame et al., 2013). Stimulating lysosome biogenesis via activation of ALP transcriptional regulator TFEB improves autophagic α-syn clearance (Decressac et al., 2013; Kilpatrick et al., 2015), and reduces α-syn toxicity in rats (Decressac et al., 2013). Enhancing lysosomal hydrolase activity also improves α-syn degradation by the ALP, as shown for the α-syn-cleaving proteases cathepsins D, B and L (Miura et al., 2014; Lehri-Boufala et al., 2015; McGlinchey and Lee, 2015) or GBA (Yang et al., 2017). Finally, rescue of lysosomal hydrolase misfolding by small molecule chaperones (Sanchez-Martinez et al., 2016; Yang et al., 2017) or enhancement of endo-lysosomal trafficking of ALP components (Chung et al., 2013; Miura et al., 2014; Tang et al., 2015) are likely to mitigate α-syn pathology.

 Other PQC Mechanisms

Other PQC mechanisms exist that are less commonly referred to in the context of α-syn pathology. α-syn synthesis could be reduced in the first place to prevent its accumulation. Several microRNAs target α-syn mRNA to reduce its expression in cell culture and in vivo (Junn et al., 2009; Doxakis, 2010; Singh and Sen, 2017). The therapeutic potential of this mechanism remains to be evaluated, especially regarding potential adverse effects of a lack of functional α-syn on the dopamine system (Abeliovich et al., 2000). Finally, unconventional secretion of misfolded proteins (misfolding-associated protein secretion, MAPS) was recently suggested to protect individual cells from misfolded proteins by delivering them to the extracellular space (Lee et al., 2016). In the context of a multicellular organism, however, this secretion might be harmful by contributing to the prion-like spreading of misfolded proteins including α-syn.

 Concluding Remarks

Extensive genetic and experimental evidence indicate that PQC deficiencies influence the development of synucleinopathies. Despite the potential of several experimental strategies targeting PQC to attenuate α-syn pathology, translation into therapy is still pending. Whether these approaches will be clinically effective, where synuclein pathology is pre-existant, remains unknown. No successful clinical trial has been reported for synucleinopathies, but targeting PQC bears great promise as such strategies have proven effective to treat diseases such as cystic fibrosis or cancer (Teicher and Tomaszewski, 2015; Hegde et al., 2017). Further functional characterization of genes associated with synucleinopathies, will provide important insights regarding the molecular mechanisms that can be targeted to enhance PQC function, boost α-syn degradation, and prevent its aggregation. For patients with familial synucleinopathies, the upcoming era of personalized medicine, including the use of patient-derived induced pluripotent-stem cells and genome-editing, might allow correction of patient-specific mutations or PQC impairments. However, in sporadic cases, where genetic contributions are unknown (the majority of PD cases), simultaneous enhancement of several components of PQC machinery will likely be necessary to stop the progression, or even reverse the course, of these devastating neurodegenerative diseases.

 Author Contributions

D-LM, BV, and TD: conception and organization of content of the mini-review. D-LM: design and generation of Figure 1, writing of introduction, and sections on α-syn pathology and defective PQC in synucleinopathies. BV: design and generation of Table 1, writing of section on therapeutic strategies, the abstract and concluding remarks, and assembly of manuscript. EF: overall revision. TD: in-depth editing of manuscript, and overall revision.

 Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding. TD is funded by a research grant through the Michael J. Fox Foundation (award number 12241). BV is funded by a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR) Fellowship program (MFE 152571). This research was undertaken thanks in part to funding from the Canada First Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives initiative.

We would like to thank Drs. Trisha Rao and Lenore Beitel for their help in reading and copy-editing this manuscript.

 References Abeliovich A. Schmitz Y. Fariñas I. Choi-Lundberg D. Ho W. H. Castillo P. E. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 239–252. 10.1016/S0896-6273(00)80886-7 Ahn M. Kim S. Kang M. Ryu Y. Doohun Kim T. (2006). Chaperone-like activities of α-synuclein: α-Synuclein assists enzyme activities of esterases. Biochem. Biophys. Res. Commun. 346 1142–1149. 10.1016/j.bbrc.2006.05.213 Alexopoulou Z. Lang J. Perrett R. M. Elschami M. Hurry M. E. D. Kim H. T. (2016). Deubiquitinase Usp8 regulates α-synuclein clearance and modifies its toxicity in Lewy body disease. Proc. Natl. Acad. Sci. U.S.A. 113 E4688–E4697. 10.1073/pnas.1523597113 Alvarez-Erviti L. Seow Y. Schapira A. H. V. Rodriguez-Oroz M. C. Obeso J. A. Cooper J. M. (2013). Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson’s disease. Cell Death Dis. 4:e545. 10.1038/cddis.2013.73 Auluck P. K. Bonini N. M. (2002). Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8 1185–1186. 10.1038/nm1102-1185 Auluck P. K. Chan H. Y. E. Trojanowski J. Q. Lee V. M. Y. Bonini N. M. (2002). Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295 865–868. 10.1126/science.1067389 Auluck P. K. Meulener M. C. Bonini N. M. (2005). Mechanisms of suppression of α-synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 280 2873–2878. 10.1074/jbc.M412106200 Bartels T. Choi J. G. Selkoe D. J. (2011). alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 107–110. 10.1038/nature10324 Batelli S. Albani D. Rametta R. Polito L. Prato F. Pesaresi M. (2008). DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson’s disease and involvement of HSP70. PLOS ONE 3:e1884. 10.1371/journal.pone.0001884 Bence N. F. Sampat R. M. Kopito R. R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 1552–1555. 10.1126/science.292.5521.1552 Bennett M. C. Bishop J. F. Leng Y. Chock P. B. Chase T. N. Mouradian M. M. (1999). Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274 33855–33858. 10.1074/jbc.274.48.33855 Bento C. F. Renna M. Ghislat G. Puri C. Ashkenazi A. Vicinanza M. (2016). Mammalian autophagy: how does it work? Annu. Rev. Biochem. 85 685–713. 10.1146/annurev-biochem-060815-014556 Beyer K. (2006). α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 112 237–251. 10.1007/s00401-006-0104-6 Braak H. Del Tredici K. Rüb U. de Vos R. A. Steur E. N. J. Braak E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24 197–211. 10.1016/S0197-4580(02)00065-9 Braun R. J. (2015). Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. Front. Mol. Neurosci. 8:8. 10.3389/fnmol.2015.00008 Burré J. Sharma M. Südhof T. C. (2014). α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl. Acad. Sci. U.S.A. 111 E4274–E4283. 10.1073/pnas.1416598111 Butler E. K. Voigt A. Lutz A. K. Toegel J. P. Gerhardt E. Karsten P. (2012). The mitochondrial chaperone protein TRAP1 mitigates alpha-Synuclein toxicity. PLOS Genet. 8:e1002488. 10.1371/journal.pgen.1002488 Büttner S. Broeskamp F. Sommer C. Markaki M. Habernig L. Alavian-Ghavanini A. (2014). Spermidine protects against α-synuclein neurotoxicity. Cell Cycle 13 3903–3908. 10.4161/15384101.2014.973309 Cantuti-Castelvetri I. Klucken J. Ingelsson M. Ramasamy K. McLean P. J. Frosch M. P. (2005). Alpha-synuclein and chaperones in dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 64 1058–1066. 10.1097/01.jnen.0000190063.90440.69 Cartier A. E. Ubhi K. Spencer B. Vazquez-Roque R. A. Kosberg K. A. Fourgeaud L. (2012). Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy. PLOS ONE 7:e34713. 10.1371/journal.pone.0034713 Caruana M. Hogen T. Levin J. Hillmer A. Giese A. Vassallo N. (2011). Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 585 1113–1120. 10.1016/j.febslet.2011.03.046 Chang D. Nalls M. A. Hallgrímsdóttir I. B. Hunkapiller J. van der Brug M. Cai F. (2017). A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat. Genet. 10.1038/ng.3955 [Epub ahead of print]. Chen L. Thiruchelvam M. J. Madura K. Richfield E. K. (2006). Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol. Dis. 23 120–126. 10.1016/j.nbd.2006.02.004 Choi H. S. Liew H. Jang A. Kim Y.-M. Lashuel H. Suh Y.-H. (2012). Phosphorylation of alpha-synuclein is crucial in compensating for proteasomal dysfunction. Biochem. Biophys. Res. Commun. 424 597–603. 10.1016/j.bbrc.2012.06.159 Chung C. Y. Khurana V. Auluck P. K. Tardiff D. F. Mazzulli J. R. Soldner F. (2013). Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342 983–987. 10.1126/science.1245296 Cuervo A. M. Stefanis L. Fredenburg R. Lansbury P. T. Sulzer D. (2004). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 1292–1295. 10.1126/science.1101738 Cuervo A. M. Wong E. (2014). Chaperone-mediated autophagy: roles in disease and aging. Cell Res. 24 92–104. 10.1038/cr.2013.153 Cullen V. Sardi S. P. Ng J. Xu Y.-H. Sun Y. Tomlinson J. J. (2011). Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann. Neurol. 69 940–953. 10.1002/ana.22400 Dagan E. Schlesinger I. Ayoub M. Mory A. Nassar M. Kurolap A. (2015). The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat. Disord. 21 1067–1071. 10.1016/j.parkreldis.2015.06.016 Dahmene M. Bérard M. Oueslati A. (2017). Dissecting the molecular pathway involved in PLK2 kinase-mediated α-Synuclein-selective autophagic degradation. J. Biol. Chem. 292 3919–3928. 10.1074/jbc.M116.759373 de Oliveira R. M. Vicente Miranda H. Francelle L. Pinho R. Szego E. M. Martinho R. (2017). The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLOS Biol. 15:e2000374. 10.1371/journal.pbio.2000374 Decressac M. Mattsson B. Weikop P. Lundblad M. Jakobsson J. Björklund A. (2013). TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc. Natl. Acad. Sci. U.S.A. 110 E1817–E1826. 10.1073/pnas.1305623110 Dettmer U. Newman A. J. Soldner F. Luth E. S. Kim N. C. von Saucken V. E. (2015). Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun. 6:7314. 10.1038/ncomms8314 DeWitt D. C. Rhoades E. (2013). alpha-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers. Biochemistry 52 2385–2387. 10.1021/bi4002369 Dimant H. Zhu L. Kibuuka L. N. Fan Z. Hyman B. T. McLean P. J. (2014). Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. PLOS ONE 9:e92098. 10.1371/journal.pone.0092098 Doxakis E. (2010). Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 285 12726–12734. 10.1074/jbc.M109.086827 Du T.-T. Wang L. Duan C.-L. Lu L.-L. Zhang J.-L. Gao G. (2015). GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy 11 1803–1820. 10.1080/15548627.2015.1086055 Du Y. Wang F. Zou J. Le W. Dong Q. Wang Z. (2014). Histone deacetylase 6 regulates cytotoxic alpha-synuclein accumulation through induction of the heat shock response. Neurobiol. Aging 35 2316–2328. 10.1016/j.neurobiolaging.2014.04.029 Dubnikov T. Ben-Gedalya T. Cohen E. (2017). Protein Quality Control in Health and Disease. Cold Spring Harb. Perspect. Biol. 9:a023523. 10.1101/cshperspect.a023523 Duennwald M. L. Echeverria A. Shorter J. (2012). Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLOS Biol. 10:e1001346. 10.1371/journal.pbio.1001346 Ebrahimi-Fakhari D. Wahlster L. McLean P. J. (2011). Molecular chaperones in Parkinson’s disease–present and future. J. Park. Dis. 1 299–320. Escusa-Toret S. Vonk W. I. Frydman J. (2013). Spatial sequestration of misfolded proteins by a dynamic chaperone pathway enhances cellular fitness during stress. Nat. Cell Biol. 15 1231–1243. 10.1038/ncb2838 Fan G.-H. Zhou H.-Y. Yang H. Chen S.-D. (2006). Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells. FEBS Lett. 580 3091–3098. 10.1016/j.febslet.2006.04.057 Filimonenko M. Stuffers S. Raiborg C. Yamamoto A. Malerød L. Fisher E. M. C. (2007). Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. J. Cell Biol. 179 485–500. 10.1083/jcb.200702115 Follett J. Bugarcic A. Yang Z. Ariotti N. Norwood S. J. Collins B. M. (2016). Parkinson disease-linked Vps35 R524W mutation impairs the endosomal association of retromer and induces α-synuclein aggregation. J. Biol. Chem. 291 18283–18298. 10.1074/jbc.M115.703157 Gan L. Vargas M. R. Johnson D. A. Johnson J. A. (2012). Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J. Neurosci. Off. J. Soc. Neurosci. 32 17775–17787. 10.1523/JNEUROSCI.3049-12.2012 Gan-Or Z. Dion P. A. Rouleau G. A. (2015). Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy 11 1443–1457. 10.1080/15548627.2015.1067364 Gao X. Carroni M. Nussbaum-Krammer C. Mogk A. Nillegoda N. B. Szlachcic A. (2015). Human Hsp70 disaggregase reverses parkinson’s-linked alpha-synuclein amyloid fibrils. Mol. Cell 59 781–793. 10.1016/j.molcel.2015.07.012 Gautam S. Karmakar S. Batra R. Sharma P. Pradhan P. Singh J. (2017). Polyphenols in combination with beta-cyclodextrin can inhibit and disaggregate alpha-synuclein amyloids under cell mimicking conditions: a promising therapeutic alternative. Biochim. Biophys. Acta 1865 589–603. 10.1016/j.bbapap.2017.02.014 Gegg M. E. Burke D. Heales S. J. R. Cooper J. M. Hardy J. Wood N. W. (2012). Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72 455–463. 10.1002/ana.23614 Goedert M. Masuda-Suzukake M. Falcon B. (2016). Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain 140(Pt 2), 266–278. 10.1093/brain/aww230 Gorbatyuk M. S. Shabashvili A. Chen W. Meyers C. Sullivan L. F. Salganik M. (2012). Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. Mol. Ther. J. Am. Soc. Gene Ther. 20 1327–1337. 10.1038/mt.2012.28 Haj-Yahya M. Fauvet B. Herman-Bachinsky Y. Hejjaoui M. Bavikar S. N. Karthikeyan S. V. (2013). Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc. Natl. Acad. Sci. U.S.A. 110 17726–17731. 10.1073/pnas.1315654110 Hartl F. U. Bracher A. Hayer-Hartl M. (2011). Molecular chaperones in protein folding and proteostasis. Nature 475 324–332. 10.1038/nature10317 Hasegawa M. Fujiwara H. Nonaka T. Wakabayashi K. Takahashi H. Lee V. M.-Y. (2002). Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. J. Biol. Chem. 277 49071–49076. 10.1074/jbc.M208046200 Hegde R. N. Subramanian A. Pothukuchi P. Parashuraman S. Luini A. (2017). Rare ER protein misfolding-mistrafficking disorders: therapeutic developments. Tissue Cell 49 175–185. 10.1016/j.tice.2017.02.001 Ho S. L. Ho P. W.-L. Pang S. Liu H. Lam C. S.-C. Leung M. C.-T. (2016). Activation of chaperone-mediated autophagy prevents accumulation of oligomeric alpha-synuclein in LRRK2 R1441G knockin mice of Parkinson’s disease. Neurology 86:5.382. Ii K. Ito H. Tanaka K. Hirano A. (1997). Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56 125–131. 10.1097/00005072-199702000-00002 Jackrel M. E. Shorter J. (2015). Engineering enhanced protein disaggregases for neurodegenerative disease. Prion 9 90–109. 10.1080/19336896.2015.1020277 Jarvela T. S. Lam H. A. Helwig M. Lorenzen N. Otzen D. E. McLean P. J. (2016). The neural chaperone proSAAS blocks alpha-synuclein fibrillation and neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 113 E4708–E4715. 10.1073/pnas.1601091113 Jinn S. Drolet R. E. Cramer P. E. Wong A. H.-K. Toolan D. M. Gretzula C. A. (2017). TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation. Proc. Natl. Acad. Sci. U.S.A. 114 2389–2394. 10.1073/pnas.1616332114 Johnston J. A. Ward C. L. Kopito R. R. (1998). Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143 1883–1898. 10.1083/jcb.143.7.1883 Junn E. Lee K.-W. Jeong B. S. Chan T. W. Im J.-Y. Mouradian M. M. (2009). Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U.S.A. 106 13052–13057. 10.1073/pnas.0906277106 Kahan B. (2011). Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. Expert Opin. Drug Saf. 10 727–749. 10.1517/14740338.2011.579898 Kilpatrick K. Zeng Y. Hancock T. Segatori L. (2015). Genetic and chemical activation of TFEB mediates clearance of aggregated α-synuclein. PLOS ONE 10:e0120819. 10.1371/journal.pone.0120819 Klucken J. Shin Y. Masliah E. Hyman B. T. McLean P. J. (2004). Hsp70 reduces alpha-synuclein aggregation and toxicity. J. Biol. Chem. 279 25497–25502. 10.1074/jbc.M400255200 Kong S. M. Chan B. K. Park J.-S. Hill K. J. Aitken J. B. Cottle L. (2014). Parkinson’s disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes. Hum. Mol. Genet. 23 2816–2833. 10.1093/hmg/ddu099 Kramer M. L. Schulz-Schaeffer W. J. (2007). Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. Off. J. Soc. Neurosci. 27 1405–1410. 10.1523/JNEUROSCI.4564-06.2007 Kumar R. Jangir D. K. Verma G. Shekhar S. Hanpude P. Kumar S. (2017). S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation. Sci. Rep. 7:44558. 10.1038/srep44558 Lastres-Becker I. Garcia-Yague A. J. Scannevin R. H. Casarejos M. J. Kugler S. Rabano A. (2016). Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson’s disease. Antioxid. Redox Signal. 25 61–77. 10.1089/ars.2015.6549 Lee J.-G. Takahama S. Zhang G. Tomarev S. I. Ye Y. (2016). Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nat. Cell Biol. 18 765–776. 10.1038/ncb3372 Lehri-Boufala S. Ouidja M.-O. Barbier-Chassefiere V. Henault E. Raisman-Vozari R. Garrigue-Antar L. (2015). New roles of glycosaminoglycans in alpha-synuclein aggregation in a cellular model of Parkinson disease. PLOS ONE 10:e0116641. 10.1371/journal.pone.0116641 Li J. Kim S. G. Blenis J. (2014). Rapamycin: one drug, many effects. Cell Metab. 19 373–379. 10.1016/j.cmet.2014.01.001 Liani E. Eyal A. Avraham E. Shemer R. Szargel R. Berg D. (2004). Ubiquitylation of synphilin-1 and α-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 101 5500–5505. 10.1073/pnas.0401081101 Lonskaya I. Desforges N. M. Hebron M. L. Moussa C. E.-H. (2013). Ubiquitination increases parkin activity to promote autophagic α-synuclein clearance. PLOS ONE 8:e83914. 10.1371/journal.pone.0083914 Luk K. C. Kehm V. Carroll J. Zhang B. O’Brien P. Trojanowski J. Q. (2012a). Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 949–953. 10.1126/science.1227157 Luk K. C. Kehm V. M. Zhang B. O’Brien P. Trojanowski J. Q. Lee V. M. Y. (2012b). Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209 975–986. 10.1084/jem.20112457 Magalhaes J. Gegg M. E. Migdalska-Richards A. Doherty M. K. Whitfield P. D. Schapira A. H. V. (2016). Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum. Mol. Genet. 25 3432–3445. 10.1093/hmg/ddw185 Maraganore D. M. Lesnick T. G. Elbaz A. Chartier-Harlin M. C. Gasser T. Kruger R. (2004). UCHL1 is a Parkinson’s disease susceptibility gene. Ann. Neurol. 55 512–521. 10.1002/ana.20017 Martinez-Vicente M. Talloczy Z. Kaushik S. Massey A. C. Mazzulli J. Mosharov E. V. (2008). Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118 777–788. 10.1172/JCI32806 Masuda-Suzukake M. Nonaka T. Hosokawa M. Oikawa T. Arai T. Akiyama H. (2013). Prion-like spreading of pathological -synuclein in brain. Brain 136 1128–1138. 10.1093/brain/awt037 Mbefo M. K. Paleologou K. E. Boucharaba A. Oueslati A. Schell H. Fournier M. (2010). Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285 2807–2822. 10.1074/jbc.M109.081950 McCann H. Stevens C. H. Cartwright H. Halliday G. M. (2014). α-Synucleinopathy phenotypes. Parkinsonism Relat. Disord. 20(Suppl. 1), S62–S67. 10.1016/S1353-8020(13)70017-8 McGlinchey R. P. Lee J. C. (2015). Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. Proc. Natl. Acad. Sci. U.S.A. 112 9322–9327. 10.1073/pnas.1500937112 McLean P. J. Kawamata H. Shariff S. Hewett J. Sharma N. Ueda K. (2002). TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J. Neurochem. 83 846–854. 10.1046/j.1471-4159.2002.01190.x Miki Y. Mori F. Tanji K. Kakita A. Takahashi H. Wakabayashi K. (2011). Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. Neuropathology 31 561–568. 10.1111/j.1440-1789.2011.01200.x Miura E. Hasegawa T. Konno M. Suzuki M. Sugeno N. Fujikake N. (2014). VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease. Neurobiol. Dis. 71 1–13. 10.1016/j.nbd.2014.07.014 Mougenot A.-L. Nicot S. Bencsik A. Morignat E. Verchère J. Lakhdar L. (2012). Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33 2225–2228. 10.1016/j.neurobiolaging.2011.06.022 Mulherkar S. A. Sharma J. Jana N. R. (2009). The ubiquitin ligase E6-AP promotes degradation of α-synuclein. J. Neurochem. 110 1955–1964. 10.1111/j.1471-4159.2009.06293.x Munoz-Lobato F. Rodriguez-Palero M. J. Naranjo-Galindo F. J. Shephard F. Gaffney C. J. Szewczyk N. J. (2014). Protective role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseases. Antioxid. Redox Signal. 20 217–235. 10.1089/ars.2012.5051 Murphy K. E. Gysbers A. M. Abbott S. K. Spiro A. S. Furuta A. Cooper A. (2015). Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 30 1639–1647. 10.1002/mds.26141 Murphy K. E. Gysbers A. M. Abbott S. K. Tayebi N. Kim W. S. Sidransky E. (2014). Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease. Brain 137(Pt 3), 834–848. 10.1093/brain/awt367 Nalls M. A. Pankratz N. Lill C. M. Do C. B. Hernandez D. G. Saad M. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46 989–993. 10.1038/ng.3043 Neumann J. Bras J. Deas E. O’Sullivan S. S. Parkkinen L. Lachmann R. H. (2009). Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132 1783–1794. 10.1093/brain/awp044 Olanow C. W. Perl D. P. DeMartino G. N. McNaught K. S. P. (2004). Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 3 496–503. 10.1016/S1474-4422(04)00827-0 Olzmann J. A. Chin L.-S. (2008). Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 4 85–87. 10.4161/auto.5172 Olzmann J. A. Li L. Chudaev M. V. Chen J. Perez F. A. Palmiter R. D. (2007). Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J. Cell Biol. 178 1025–1038. 10.1083/jcb.200611128 Opattova A. Cente M. Novak M. Filipcik P. (2015). The ubiquitin proteasome system as a potential therapeutic target for treatment of neurodegenerative diseases. Gen. Physiol. Biophys. 34 337–352. 10.4149/gpb_2015024 Orenstein S. J. Kuo S.-H. Tasset I. Arias E. Koga H. Fernandez-Carasa I. (2013). Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16 394–406. 10.1038/nn.3350 Osellame L. D. Duchen M. R. (2013). Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases. Autophagy 9 1633–1635. 10.4161/auto.25878 Osellame L. D. Rahim A. A. Hargreaves I. P. Gegg M. E. Richard-Londt A. Brandner S. (2013). Mitochondria and quality control defects in a mouse model of gaucher disease—links to Parkinson’s disease. Cell Metab. 17 941–953. 10.1016/j.cmet.2013.04.014 Oueslati A. Schneider B. L. Aebischer P. Lashuel H. A. (2013). Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. U.S.A. 110 E3945–E3954. 10.1073/pnas.1309991110 Outeiro T. F. Putcha P. Tetzlaff J. E. Spoelgen R. Koker M. Carvalho F. (2008). Formation of toxic oligomeric alpha-synuclein species in living cells. PLOS ONE 3:e1867. 10.1371/journal.pone.0001867 Passmore L. A. Barford D. (2004). Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochem. J. 379 513–525. 10.1042/BJ20040198 Peterson L. F. Sun H. Liu Y. Potu H. Kandarpa M. Ermann M. (2015). Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood 125 3588–3597. 10.1182/blood-2014-10-605584 Pratt W. B. Gestwicki J. E. Osawa Y. Lieberman A. P. (2015). Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 55 353–371. 10.1146/annurev-pharmtox-010814-124332 Putcha P. Danzer K. M. Kranich L. R. Scott A. Silinski M. Mabbett S. (2010). Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 332 849–857. 10.1124/jpet.109.158436 Ramirez A. Heimbach A. Grundemann J. Stiller B. Hampshire D. Cid L. P. (2006). Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38 1184–1191. 10.1038/ng1884 Ren R. Shi C. Cao J. Sun Y. Zhao X. Guo Y. (2016). Neuroprotective effects of a standardized flavonoid extract of safflower against neurotoxin-induced cellular and animal models of Parkinson’s disease. Sci. Rep. 6:22135. 10.1038/srep22135 Roberts R. F. Tang M. Y. Fon E. A. Durcan T. M. (2016). Defending the mitochondria: the pathways of mitophagy and mitochondrial-derived vesicles. Int. J. Biochem. Cell Biol. 79 427–436. 10.1016/j.biocel.2016.07.020 Rodriguez J. A. Ivanova M. I. Sawaya M. R. Cascio D. Reyes F. E. Shi D. (2015). Structure of the toxic core of alpha-synuclein from invisible crystals. Nature 525 486–490. 10.1038/nature15368 Roeters S. J. Iyer A. Pletikapiæ G. Kogan V. Subramaniam V. Woutersen S. (2017). Evidence for intramolecular antiparallel beta-sheet structure in alpha-synuclein fibrils from a combination of two-dimensional infrared spectroscopy and atomic force microscopy. Sci. Rep. 7:41051. 10.1038/srep41051 Rothaug M. Zunke F. Mazzulli J. R. Schweizer M. Altmeppen H. Lüllmann-Rauch R. (2014). LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. Proc. Natl. Acad. Sci. U.S.A. 111 15573–15578. 10.1073/pnas.1405700111 Rott R. Szargel R. Haskin J. Bandopadhyay R. Lees A. J. Shani V. (2011). alpha-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc. Natl. Acad. Sci. U.S.A. 108 18666–18671. 10.1073/pnas.1105725108 Rott R. Szargel R. Haskin J. Shani V. Shainskaya A. Manov I. (2008). Monoubiquitylation of α-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem. 283 3316–3328. 10.1074/jbc.M704809200 Sahu R. Kaushik S. Clement C. C. Cannizzo E. S. Scharf B. Follenzi A. (2011). Microautophagy of cytosolic proteins by late endosomes. Dev. Cell 20 131–139. 10.1016/j.devcel.2010.12.003 Sala G. Marinig D. Arosio A. Ferrarese C. (2016). Role of chaperone-mediated autophagy dysfunctions in the pathogenesis of Parkinson’s Disease. Front. Mol. Neurosci. 9:157. 10.3389/fnmol.2016.00157 Salganik M. Sergeyev V. G. Shinde V. Meyers C. A. Gorbatyuk M. S. Lin J. H. (2015). The loss of glucose-regulated protein 78 (GRP78) during normal aging or from siRNA knockdown augments human alpha-synuclein (alpha-syn) toxicity to rat nigral neurons. Neurobiol. Aging 36 2213–2223. 10.1016/j.neurobiolaging.2015.02.018 Sanchez-Martinez A. Beavan M. Gegg M. E. Chau K.-Y. Whitworth A. J. Schapira A. H. V. (2016). Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci. Rep. 6:31380. 10.1038/srep31380 Schlossmacher M. G. Frosch M. P. Gai W. P. Medina M. Sharma N. Forno L. (2002). Parkin localizes to the lewy bodies of Parkinson disease and dementia with lewy bodies. Am. J. Pathol. 160 1655–1667. 10.1016/S0002-9440(10)61113-3 Senior S. L. Ninkina N. Deacon R. Bannerman D. Buchman V. L. Cragg S. J. (2008). Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci. 27 947–957. 10.1111/j.1460-9568.2008.06055.x Shahpasandzadeh H. Popova B. Kleinknecht A. Fraser P. E. Outeiro T. F. Braus G. H. (2014). Interplay between sumoylation and phosphorylation for protection against α-synuclein inclusions. J. Biol. Chem. 289 31224–31240. 10.1074/jbc.M114.559237 Sharma S. K. Priya S. (2017). Expanding role of molecular chaperones in regulating alpha-synuclein misfolding; implications in Parkinson’s disease. Cell. Mol. Life Sci. 74 617–629. 10.1007/s00018-016-2340-9 Shimura H. Hattori N. Kubo S. Mizuno Y. Asakawa S. Minoshima S. (2000). Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 302–305. 10.1038/77060 Shin Y. Klucken J. Patterson C. Hyman B. T. McLean P. J. (2005). The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280 23727–23734. 10.1074/jbc.M503326200 Shorter J. (2016). Engineering therapeutic protein disaggregases. Mol. Biol. Cell 27 1556–1560. 10.1091/mbc.E15-10-0693 Singh A. Sen D. (2017). MicroRNAs in Parkinson’s disease. Exp. Brain Res. 235 2359–2374. 10.1007/s00221-017-4989-1 Skibinski G. Hwang V. Ando D. M. Daub A. Lee A. K. Ravisankar A. (2017). Nrf2 mitigates LRRK2- and alpha-synuclein-induced neurodegeneration by modulating proteostasis. Proc. Natl. Acad. Sci. U.S.A. 114 1165–1170. 10.1073/pnas.1522872114 Snyder H. Mensah K. Theisler C. Lee J. Matouschek A. Wolozin B. (2003). Aggregated and monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278 11753–11759. 10.1074/jbc.M208641200 Sontag E. M. Samant R. S. Frydman J. (2017). Mechanisms and functions of spatial protein quality control. Annu. Rev. Biochem. 86 97–122. 10.1146/annurev-biochem-060815-014616 Souza J. M. Giasson B. I. Lee V. M. Y. Ischiropoulos H. (2000). Chaperone-like activity of synucleins. FEBS Lett. 474 116–119. 10.1016/S0014-5793(00)01563-5 Spencer B. Potkar R. Trejo M. Rockenstein E. Patrick C. Gindi R. (2009). Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in α-synuclein models of Parkinson’s and Lewy body diseases. J. Neurosci. 29 13578–13588. 10.1523/JNEUROSCI.4390-09.2009 Stefanis L. (2012). α-synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2:a009399. 10.1101/cshperspect.a009399 Stefanis L. Larsen K. E. Rideout H. J. Sulzer D. Greene L. A. (2001). Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. Off. J. Soc. Neurosci. 21 9549–9560. Tanaka M. Kim Y. M. Lee G. Junn E. Iwatsubo T. Mouradian M. M. (2004). Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279 4625–4631. 10.1074/jbc.M310994200 Tanaka Y. Engelender S. Igarashi S. Rao R. K. Wanner T. Tanzi R. E. (2001). Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10 919–926. 10.1093/hmg/10.9.919 Tang F.-L. Erion J. R. Tian Y. Liu W. Yin D.-M. Ye J. (2015). VPS35 in dopamine neurons is required for endosome-to-golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for alpha-synuclein degradation and prevention of pathogenesis of Parkinson’s disease. J. Neurosci. Off. J. Soc. Neurosci. 35 10613–10628. 10.1523/JNEUROSCI.0042-15.2015 Teicher B. A. Tomaszewski J. E. (2015). Proteasome inhibitors. Biochem. Pharmacol. 96 1–9. 10.1016/j.bcp.2015.04.008 Tenreiro S. Reimao-Pinto M. M. Antas P. Rino J. Wawrzycka D. Macedo D. (2014). Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson’s disease. PLOS Genet. 10:e1004302. 10.1371/journal.pgen.1004302 Tetzlaff J. E. Putcha P. Outeiro T. F. Ivanov A. Berezovska O. Hyman B. T. (2008). CHIP targets toxic alpha-Synuclein oligomers for degradation. J. Biol. Chem. 283 17962–17968. 10.1074/jbc.M802283200 Tian T. Sun Y. Wu H. Pei J. Zhang J. Zhang Y. (2016). Acupuncture promotes mTOR-independent autophagic clearance of aggregation-prone proteins in mouse brain. Sci. Rep. 6:19714. 10.1038/srep19714 Tofaris G. K. Kim H. T. Hourez R. Jung J.-W. Kim K. P. Goldberg A. L. (2011). Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal–lysosomal pathway. Proc. Natl. Acad. Sci. U.S.A. 108 17004–17009. 10.1073/pnas.1109356108 Trinh J. Farrer M. (2013). Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 9 445–454. 10.1038/nrneurol.2013.132 Tsunemi T. Krainc D. (2014). Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum. Mol. Genet. 23 2791–2801. 10.1093/hmg/ddt572 Usenovic M. Tresse E. Mazzulli J. R. Taylor J. P. Krainc D. (2012). Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J. Neurosci. 32 4240–4246. 10.1523/JNEUROSCI.5575-11.2012 Vogiatzi T. Xilouri M. Vekrellis K. Stefanis L. (2008). Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283 23542–23556. 10.1074/jbc.M801992200 Volpicelli-Daley L. A. Luk K. C. Patel T. P. Tanik S. A. Riddle D. M. Stieber A. (2011). Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72 57–71. 10.1016/j.neuron.2011.08.033 Wakabayashi K. Hayashi S. Kakita A. Yamada M. Toyoshima Y. Yoshimoto M. (1998). Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 96 445–452. 10.1007/s004010050918 Wolff S. Weissman J. S. Dillin A. (2014). Differential scales of protein quality control. Cell 157 52–64. 10.1016/j.cell.2014.03.007 Wyatt A. R. Yerbury J. J. Ecroyd H. Wilson M. R. (2013). Extracellular chaperones and proteostasis. Annu. Rev. Biochem. 82 295–322. 10.1146/annurev-biochem-072711-163904 Xia Q. Liao L. Cheng D. Duong D. M. Gearing M. Lah J. J. (2008). Proteomic identification of novel proteins associated with Lewy bodies. Front. Biosci. J. Virtual Libr. 13:3850–3856. 10.2741/2973 Xilouri M. Brekk O. R. Kirik D. Stefanis L. (2013). LAMP2A as a therapeutic target in Parkinson disease. Autophagy 9 2166–2168. 10.4161/auto.26451 Xilouri M. Brekk O. R. Polissidis A. Chrysanthou-Piterou M. Kloukina I. Stefanis L. (2016). Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy 12 2230–2247. 10.1080/15548627.2016.1214777 Xilouri M. Vogiatzi T. Vekrellis K. Park D. Stefanis L. (2009). Abberant α-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLOS ONE 4:e5515. 10.1371/journal.pone.0005515 Yang S.-Y. Beavan M. Chau K.-Y. Taanman J.-W. Schapira A. H. V. (2017). A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers. Stem Cell Rep. 8 728–742. 10.1016/j.stemcr.2017.01.011 Yu F. Xu H. Zhuo M. Sun L. Dong A. Liu X. (2005). Impairment of redox state and dopamine level induced by alpha-synuclein aggregation and the prevention effect of hsp70. Biochem. Biophys. Res. Commun. 331 278–284. 10.1016/j.bbrc.2005.03.148 Zhou W. Bercury K. Cummiskey J. Luong N. Lebin J. Freed C. R. (2011). Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J. Biol. Chem. 286 14941–14951. 10.1074/jbc.M110.211029 Zhou Y. Gu G. Goodlett D. R. Zhang T. Pan C. Montine T. J. (2004). Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J. Biol. Chem. 279 39155–39164. 10.1074/jbc.M405456200 Abbreviations α-syn

α-synuclein

 ALP

autophagy-lysosome pathway

 CHIP

carboxyl terminus of Hsp70-interacting protein

 CMA

chaperone-mediated autophagy

 E6AP

E6 associated protein

 GBA

β-glucocerebrosidase

 Hsc

heat shock cognate

 Hsp

heat shock protein

 LB

Lewy bodies

 LBD

Lewy body dementia

 MPTP

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

 MSA

multiple system atrophy

 NAC

non-amyloid-β component

 PD

Parkinson’s disease

 PQC

protein quality control

 SIAH

seven in absentia homolog

 Ub

ubiquitin

 UPS

ubiquitin-proteasome system.